LOS ANGELES, CA / ACCESSWIRE / March 23, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Innocoll Holdings plc (“Innocoll” or the “Company”) (INNL) concerning possible violations of federal securities laws between March 17, 2016 and December 29, 2016, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the March 27, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, Innocoll failed to disclose that it’s New Drug Application submission to the U.S. Food and Drug Administration in October 2016 for XARACOLL was unsuccessful and because of this, XARACOLL could not be approved in 2017. Innocoll then received a Refusal to File letter from the FDA. When this information was announced to the public, the value of Innocoll stock dropped, causing shareholders harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/